Clinical Trial Update: An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma

View source ↗

Summary

An observational study completed in Ukraine evaluated the safety and efficacy of Humacyte's human acellular vessel (HAV) for arterial replacement or reconstruct…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Vascular Injury

Drugs mentioned

• Humacyte Human Acellular Vessel (HAV) (human acellular vessel)

Snippet

Sponsor: Humacyte, Inc. | Conditions: Trauma, Trauma Injury | Status: COMPLETED